Xuechen Chen1, Yuan Zhang1, Qian Chen1, Qing Li1, Yanping Li1, Wenhua Ling2. 1. From the Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou, China (X.C., Q.C., Y.L., W.L.); Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou, China (X.C., Q.C., Y.L., W.L.); Department of Cardiology, General Hospital of Guangzhou Military Command of People's Liberation Army, China (Y.Z.); and Department of Epidemiology, School of Public Health, Guilin Medical University, China (Q.L.). 2. From the Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou, China (X.C., Q.C., Y.L., W.L.); Guangdong Provincial Key Laboratory of Food, Nutrition, and Health, Department of Nutrition, School of Public Health, Sun Yat-Sen University, Guangzhou, China (X.C., Q.C., Y.L., W.L.); Department of Cardiology, General Hospital of Guangzhou Military Command of People's Liberation Army, China (Y.Z.); and Department of Epidemiology, School of Public Health, Guilin Medical University, China (Q.L.). lingwh@mail.sysu.edu.cn.
Abstract
OBJECTIVE: The present study was designed to evaluate the association of circulating fetuin-A with cardiovascular disease (CVD) and all-cause mortality. APPROACH AND RESULTS: We measured plasma fetuin-A in 1620 patients using an enzyme-linked immunosorbent assay kit. The patients were members of the Guangdong coronary artery disease cohort and were recruited between October 2008 and December 2011. Cox regression models were used to estimate the association between plasma fetuin-A and the risk of mortality. A total of 206 deaths were recorded during a median follow-up of 5.9 years, 146 of whom died from CVD. The hazard ratios for the second and third tertiles of the fetuin-A levels (using the first tertile as a reference) were 0.65 (95% confidence interval, 0.44-0.96) and 0.51 (95% confidence interval, 0.33-0.78) for CVD mortality (P=0.005) and 0.65 (95% confidence interval, 0.47-0.91) and 0.48 (95% confidence interval, 0.33-0.70) for all-cause mortality (P<0.001), respectively. CONCLUSIONS: Lower plasma fetuin-A levels were associated with an increased risk of all-cause and CVD mortality in patients with coronary artery disease independently of traditional CVD risk factors.
OBJECTIVE: The present study was designed to evaluate the association of circulating fetuin-A with cardiovascular disease (CVD) and all-cause mortality. APPROACH AND RESULTS: We measured plasma fetuin-A in 1620 patients using an enzyme-linked immunosorbent assay kit. The patients were members of the Guangdong coronary artery disease cohort and were recruited between October 2008 and December 2011. Cox regression models were used to estimate the association between plasma fetuin-A and the risk of mortality. A total of 206 deaths were recorded during a median follow-up of 5.9 years, 146 of whom died from CVD. The hazard ratios for the second and third tertiles of the fetuin-A levels (using the first tertile as a reference) were 0.65 (95% confidence interval, 0.44-0.96) and 0.51 (95% confidence interval, 0.33-0.78) for CVD mortality (P=0.005) and 0.65 (95% confidence interval, 0.47-0.91) and 0.48 (95% confidence interval, 0.33-0.70) for all-cause mortality (P<0.001), respectively. CONCLUSIONS: Lower plasma fetuin-A levels were associated with an increased risk of all-cause and CVD mortality in patients with coronary artery disease independently of traditional CVD risk factors.
Authors: Albert Topf; Moritz Mirna; Vera Paar; Lukas J Motloch; Nina Bacher; Marcus Franz; Uta C Hoppe; Daniel Kretzschmar; Michael Lichtenauer Journal: J Clin Med Date: 2022-05-25 Impact factor: 4.964
Authors: P Borsky; Z Fiala; C Andrys; M Beranek; K Hamakova; J Kremlacek; A Malkova; T Svadlakova; J Krejsek; V Palicka; V Rehacek; L Kotingova; L Borska Journal: Physiol Res Date: 2021-05-12 Impact factor: 1.881
Authors: Piotr Skrzypczyk; Anna Stelmaszczyk-Emmel; Michał Szyszka; Anna Ofiara; Małgorzata Pańczyk-Tomaszewska Journal: Pediatr Nephrol Date: 2021-02-18 Impact factor: 3.714